<DOC>
	<DOCNO>NCT01071083</DOCNO>
	<brief_summary>This randomize , rater blind trial patient interrupt treatment natalizumab without treated immunomodulatory drug , continue treatment natalizumab . The main purpose study find follow , participant stop take natalizumab 24 week : - MS symptom return , - drug MS may help control MS symptom natalizumab-interruption period . This study also explore quickly effect natalizumab return resume natalizumab dosing .</brief_summary>
	<brief_title>Treatment Interruption Natalizumab</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Major criterion include : A diagnosis relapse form MS Treatment natalizumab accord locally approve prescribing information Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>MS</keyword>
</DOC>